Conference
FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)
Authors
Moore K; Oza A; Colombo N; Oaknin A; Scambia G; Lorusso D; Farias-Eisner R; Banerjee S; Murphy C; Tanyi J
Volume
30
Publisher
OXFORD UNIV PRESS
Publication Date
October 1, 2019
Name of conference
44th Congress of the European-Society-for-Medical-Oncology (ESMO)
Conference place
Barcelona, SPAIN
Conference start date
September 27, 2019
Conference end date
October 1, 2019
Conference proceedings
ANNALS OF ONCOLOGY
ISSN
0923-7534